

Fresenius Kabi Canada Ltd.

165 Galaxy Blvd, Suite 100 Toronto, Ontario Canada M9W 0C8 T: 905.770.3711

F: 844.513.1522 W: fresenius-kabi.ca

June 23, 2023

<u>Dipyridamole Injection, USP 5 mg/mL SD Vial 10 mL</u> <u>Allocations Update</u>

Dear Valued Customer,

Based on customer feedback, Fresenius Kabi Canada would like to advised that July allocations for our **Dipyridamole Injection**, **USP 5 mg/mL SD Vial 10 mL** will be made available next week due to the urgent need for this product. Effective **June 26**, **2023**, July allocations will be released and as previously communicated, will represent approximately **50% of contract customers' historical monthly demand**.

Please ensure all allocations are pulled before June 30, 2023, as they will not carry over into July. As a result, we will be on backorder effective July 1, 2023.

DIN	Fresenius Kabi Product Code	MDP Product Code	McKesson Product Code	Product Description	Supply Status Jun. 26, 2023	Supply Status Jul. 2023	Supply Status Aug. 2023
02244475	C601310	921014	600262	Dipyridamole Injection, USP 5 mg/mL SD Vial 10 mL	July allocations to be made available representing approximately 50% of contract customers' historical monthly demand.	Backorder*	Backorder (Resupply Aug. 18)

^{*}Please note that the stockout date may vary by region, please check your local distribution centre for availability.

All efforts are being made to expedite availability and mitigate this shortage. In the interim, we encourage all customers to use severe conservation measures to extend the supply as long as possible.

We recognize the difficulties and inconvenience that you may encounter as a result of our reduced allocations and supply interruption, and we thank you for your patience and understanding in this matter.

If you have any questions or concerns, please do not hesitate to contact your sales representative.

Sincerely,

Joseph Le

Senior Manager, Commercial Operations & Analytics

joseph.le@fresenius-kabi.com